INT248295

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.21
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 0.80
Pain Relevance 0.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Tnfsf13b) extracellular region (Tnfsf13b) plasma membrane (Tnfsf13b)
Anatomy Link Frequency
B lymphocyte 2
Tnfsf13b (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 28 65.36 Quite High
Inflammation 25 42.48 Quite Low
chemokine 6 33.16 Quite Low
rheumatoid arthritis 24 24.40 Low Low
abatacept 10 5.00 Very Low Very Low Very Low
Arthritis 9 5.00 Very Low Very Low Very Low
corticosteroid 5 5.00 Very Low Very Low Very Low
Infliximab 3 5.00 Very Low Very Low Very Low
methotrexate 3 5.00 Very Low Very Low Very Low
cva 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Aging 1 95.20 Very High Very High Very High
Systemic Lupus Erythematosus 104 94.74 High High
Renal Disease 44 85.76 High High
Disease 38 80.52 Quite High
Autoimmune Disease 10 58.08 Quite High
INFLAMMATION 25 42.48 Quite Low
Recurrence 12 37.36 Quite Low
Apoptosis 6 28.52 Quite Low
Rheumatoid Arthritis 24 24.40 Low Low
Infection 10 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It is a soluble transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI) receptor and binds BLyS and APRIL with antagonistic effects.
BLyS Binding (binds) of
1) Confidence 0.21 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2943198 Disease Relevance 0.43 Pain Relevance 0.03
For these patients alternative approaches may be considered, interfering with, for example, APRIL (a proliferation-inducing ligand) and B lymphocyte stimulator (BLyS).
BLyS Binding (interfering) of in B lymphocyte
2) Confidence 0.18 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564787 Disease Relevance 0.10 Pain Relevance 0
High serum levels of soluble BLyS, and its homolog APRIL (a proliferation inducing ligand), are found in patients with SLE; in murine lupus, selective blockade of BLyS reduces transitional type 2 follicular and marginal-zone B-cells, and significantly attenuates immune activation.21 In a Phase II double-blind placebo-controlled trial belimumab, a human monoclonal antibody to BLyS which prevents the binding of soluble BLyS to its receptors, failed to meet its endpoints at 24 weeks22 but a post hoc analysis by week 52 suggested that belimumab reduces activity and prevents flares.
BLyS Binding (binding) of in B-cells associated with systemic lupus erythematosus
3) Confidence 0.14 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2943198 Disease Relevance 0.27 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox